314 related articles for article (PubMed ID: 20486731)
1. Infliximab paediatric Crohn's disease educational plan: a European, cross-sectional, multicentre evaluation.
Arana A; Allen S; Burkowitz J; Fantoni V; Ghatnekar O; Rico MT; Vanhaverbeke N; Wentworth CE; Brosa M; Arellano FM
Drug Saf; 2010 Jun; 33(6):489-501. PubMed ID: 20486731
[TBL] [Abstract][Full Text] [Related]
2. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
3. Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on Crohn's disease: a real-life survey in Spain.
Hinojosa J; Gisbert JP; Gomollón F; López San Román A
J Crohns Colitis; 2012 Aug; 6(7):763-70. PubMed ID: 22398092
[TBL] [Abstract][Full Text] [Related]
4. Access to biologicals in Crohn's disease in ten European countries.
Péntek M; Lakatos PL; Oorsprong T; Gulácsi L; Pavlova M; Groot W; Rencz F; Brodszky V; Baji P; Crohn's Disease Research Group
World J Gastroenterol; 2017 Sep; 23(34):6294-6305. PubMed ID: 28974896
[TBL] [Abstract][Full Text] [Related]
5. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
6. Gastroenterologists' prescribing of infliximab for Crohn's disease: a national survey.
St Charles M; Smith SR; Beardsley R; Fedder DO; Carter-Pokras O; Cross RK
Inflamm Bowel Dis; 2009 Oct; 15(10):1467-75. PubMed ID: 19266574
[TBL] [Abstract][Full Text] [Related]
7. Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease.
Panagi S; Palka W; Korelitz BI; Taskin M; Lessnau KD
Inflamm Bowel Dis; 2004 May; 10(3):274-7. PubMed ID: 15290924
[TBL] [Abstract][Full Text] [Related]
8. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Sandborn WJ; Hanauer SB
Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
[TBL] [Abstract][Full Text] [Related]
9. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management.
Johnson FR; Hauber B; Özdemir S; Siegel CA; Hass S; Sands BE
J Manag Care Pharm; 2010 Oct; 16(8):616-28. PubMed ID: 20866166
[TBL] [Abstract][Full Text] [Related]
10. Remicade does not abolish the need for surgery in fistulizing Crohn's disease.
Poritz LS; Rowe WA; Koltun WA
Dis Colon Rectum; 2002 Jun; 45(6):771-5. PubMed ID: 12072629
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of repeated treatment with infliximab in patients with Crohn's disease: a retrospective data analysis in Germany.
Witthöft T; Ludwig D
Int J Colorectal Dis; 2005 Jan; 20(1):18-23. PubMed ID: 15459773
[TBL] [Abstract][Full Text] [Related]
12. Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up.
Wenzl HH; Reinisch W; Jahnel J; Stockenhuber F; Tilg H; Kirchgatterer A; Petritsch W
Eur J Gastroenterol Hepatol; 2004 Aug; 16(8):767-73. PubMed ID: 15256978
[TBL] [Abstract][Full Text] [Related]
13. Infliximab (Remicade), a new biological treatment for Crohn's disease.
D'Haens GR
Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573
[TBL] [Abstract][Full Text] [Related]
14. Response to infliximab is related to disease duration in paediatric Crohn's disease.
Lionetti P; Bronzini F; Salvestrini C; Bascietto C; Canani RB; Dé Angelis GL; Guariso G; Martelossi S; Papadatou B; Barabino A
Aliment Pharmacol Ther; 2003 Aug; 18(4):425-31. PubMed ID: 12940928
[TBL] [Abstract][Full Text] [Related]
15. Understanding the role of the primary care physician in the management of patients with Crohn's perianal fistulas.
Salinas GD; Belcher E; Stacy S; Nazarey PP; Cazzetta SE
Postgrad Med; 2024 Jan; 136(1):67-77. PubMed ID: 38445664
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
Ye BD; Pesegova M; Alexeeva O; Osipenko M; Lahat A; Dorofeyev A; Fishman S; Levchenko O; Cheon JH; Scribano ML; Mateescu RB; Lee KM; Eun CS; Lee SJ; Lee SY; Kim H; Schreiber S; Fowler H; Cheung R; Kim YH
Lancet; 2019 Apr; 393(10182):1699-1707. PubMed ID: 30929895
[TBL] [Abstract][Full Text] [Related]
17. Risks and benefits of infliximab for the treatment of Crohn's disease.
Siegel CA; Hur C; Korzenik JR; Gazelle GS; Sands BE
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1017-24; quiz 976. PubMed ID: 16843733
[TBL] [Abstract][Full Text] [Related]
18. Practice patterns in the use of anti-tumor necrosis factor alpha agents in the management of Crohn's disease: a US national practice survey comparing experts and non-experts.
Swaminath A; Lebwohl B; Capiak KM; Present DH
Dig Dis Sci; 2011 Apr; 56(4):1160-4. PubMed ID: 21181440
[TBL] [Abstract][Full Text] [Related]
19. Infliximab in treatment of Crohn's disease: the Milan experience.
Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G
Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788
[TBL] [Abstract][Full Text] [Related]
20. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
Keating GM; Perry CM
BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
